Hematologic Disorder

0
Pipeline Programs
5
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Hemab Therapeutics
Hemab TherapeuticsDenmark - Copenhagen
1 program
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersN/A1 trial
Active Trials
NCT04398628Recruiting3,000Est. Dec 2035
Sanofi
SanofiPARIS, France
1 program
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersN/A
Pfizer
PfizerNEW YORK, NY
1 program
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersN/A
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersN/A
CSL Behring
CSL BehringIL - Bradley
1 program
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Hemab TherapeuticsATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Clinical Trials (1)

Total enrollment: 3,000 patients across 1 trials

NCT04398628Hemab TherapeuticsATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Start: Sep 2020Est. completion: Dec 20353,000 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 3,000 patients
5 companies competing in this space